Activity of AZD2563, a novel oxazolidinone, against Staphylococcus aureus strains with reduced susceptibility to vancomycin or linezolid.
The susceptibilities of clinical vancomycin-intermediate Staphylococcus aureus (VISA), heterogeneous VISA, and laboratory-generated linezolid-resistant S. aureus strains to the new oxazolidinone AZD2563 were assessed by agar dilution MIC determination. All clinical strains were susceptible to linezolid, and the linezolid MICs for them were equal to or twofold higher than those of AZD2563. Cross-resistance with linezolid was seen in laboratory-generated mutants, and for these strains the MIC of AZD2563 was twofold higher than that of linezolid.
Bristol Centre for Antimicrobial Research and Evaluation, Department of Medical Microbiology, Southmead Hospital, and Department of Pathology and Microbiology, School of Medical Sciences, Clifton, United Kingdom. robin.howe@north-bristol.swest.nhs.uk
Robin A
RA
Howe
Mandy
M
Wootton
Alan R
AR
Noel
Karen E
KE
Bowker
Timothy R
TR
Walsh
Alasdair P
AP
MacGowan
D000081:Acetamides / Q000494:pharmacology*; D000890:Anti-Infective Agents / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial / Q000235:genetics; D006801:Humans; D000069349:Linezolid; D008826:Microbial Sensitivity Tests; D023303:Oxazolidinones / Q000494:pharmacology*; D013203:Staphylococcal Infections / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000235:genetics; D020713:Vancomycin Resistance / Q000235:genetics
D000081:Acetamides; D000890:Anti-Infective Agents; D023303:Oxazolidinones; C453362:posizolid; D000069349:Linezolid